Xeljanz Den europeiske union - norsk - EMA (European Medicines Agency)

xeljanz

pfizer europe ma eeig - tofacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Ytracis Den europeiske union - norsk - EMA (European Medicines Agency)

ytracis

cis bio international - yttrium (90y) chloride - radionuklide bildebehandling - diagnostiske radiopharmaceuticals - brukes kun til radioaktivt merking av bærermolekyler som er spesielt utviklet og godkjent for radioaktivt merking med dette radionuklid. radiopharmaceutical precursor - not intended for direct application to patients.

Zalviso Den europeiske union - norsk - EMA (European Medicines Agency)

zalviso

fgk representative service gmbh - sufentanil - smerte, postoperativ - anestetika - zalviso er indisert for behandling av akutt moderat til alvorlig postoperativ smerte hos voksne pasienter.

Galliprant Den europeiske union - norsk - EMA (European Medicines Agency)

galliprant

elanco gmbh - grapiprant - andre betennelsesdempende og antirheumatic midler, ikke-steroider - hunder - for behandling av smerte assosiert med mild til moderat slitasjegikt hos hunder.

Abstral 600 mikrog Norge - norsk - Statens legemiddelverk

abstral 600 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 600 mikrog

Abstral 100 mikrog Norge - norsk - Statens legemiddelverk

abstral 100 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 100 mikrog

Abstral 200 mikrog Norge - norsk - Statens legemiddelverk

abstral 200 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 200 mikrog

Abstral 300 mikrog Norge - norsk - Statens legemiddelverk

abstral 300 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 300 mikrog

Abstral 400 mikrog Norge - norsk - Statens legemiddelverk

abstral 400 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 400 mikrog

Abstral 800 mikrog Norge - norsk - Statens legemiddelverk

abstral 800 mikrog

kyowa kirin holdings b.v. - fentanylsitrat - sublingvaltablett - 800 mikrog